Rhinitis
+2
To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
Sponsored by UCB Pharma
About this trial
Last updated 12 years ago
Study ID
A00348
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
18 to 60 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 22 years ago
What is this trial about?
To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of
Seasonal Allergic Rhinitis
What are the participation requirements?
Inclusion Criteria
- Male or female, 18 to 60 years old, inclusive
- two-year history of allergic rhinitis due to tree, grass or weed pollen
- sufficient histamine-dependent symptoms of rhinitis during the selection week (T5SS ≥ 5)
Exclusion Criteria
- An ear, nose or throat (ENT) infection
- asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn
- atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment
- an associated ENT disease
- use of decongestants
- nasal or ocular topical treatment